Nucleate Podcast Breakthrough: The stories behind Life-Changing Therapies with Dr. William Pao
Jun 11, 2025
Dr. William Pao, CEO and co-founder of Revelio Therapeutics, shares his compelling journey from losing his father to colon cancer at 13 to spearheading breakthroughs in lung cancer research. He discusses the discovery of EGFR mutations and the fierce competition in publishing this pivotal finding. Dr. Pao highlights the serendipitous origins of Tylenol and delves into drug development challenges in the biotech world. He offers valuable insights on resilience for aspiring entrepreneurs and the future of medical innovation.
AI Snips
Chapters
Books
Transcript
Episode notes
Pao's EGFR Mutation Publishing Scoop
- William Pao experienced being scooped in publishing key findings about EGFR mutations in lung cancer, which was disheartening but common in academia.
- He quickly moved on to contribute additional critical findings, showing resilience and extending the research impact.
Balance Data Sharing and Protection
- Science progresses best when data is shared openly and rapidly, such as via preprints and collaborative meetings.
- Though competing interests exist, balancing open science with protecting ideas is necessary for innovation.
SMA Foundation's Impact
- The SMA Foundation, started by families of affected children, played a pivotal role in developing therapies by funding research and engaging in drug development boards.
- Patient groups can be powerful catalysts for progress in rare diseases.